Search

Displaying results 751 - 760 of 4588 in total
  1. Pathway

    Physostigmine Action Pathway (new)

    smpdb.ca/view/SMP0126616
    Drug action

    Physostigmine is a cholinesterase inhibitor used to treat glaucoma, once administered it is rapidly absorbed and can travel across membranes even the blood-brain barrier. Physostigmine acts on the acetylcholinesterase enzyme and inhibits...

    Drugs: Choline · Physostigmine · Calcium · Magnesium cation · Acetylcholine · Acetic acid
    Enzymes: High affinity choline transporter 1
  2. Pathway

    Tacrine Action Pathway (new)

    smpdb.ca/view/SMP0126621
    Drug action

    Its mechanism of action is not fully known but is thought that the drug reversibly binds and inhibits cholinesterase and acetylcholinesterase.

    Drugs: Choline · Tacrine · Calcium · Magnesium cation · Acetylcholine · Acetic acid
    Enzymes: High affinity choline transporter 1
  3. Drug

    Cefonicid

    go.drugbank.com/drugs/DB01328
    Approved

    A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and sof...

  4. Drug

    Ajmaline

    go.drugbank.com/drugs/DB01426
    ApprovedWithdrawn

    It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials.

  5. Drug

    Lopinavir

    go.drugbank.com/drugs/DB01601
    ApprovedInvestigational

    [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself … [A191757] Lopinavir was previously under investigation in combination with ritonavir for the treatment of COVID-19 caused by SARS-CoV-2.[L12012]

  6. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors

  7. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). … Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology.

  8. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

  9. Drug

    Brigatinib

    go.drugbank.com/drugs/DB12267
    ApprovedInvestigational

    [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]

  10. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010.